Prevalence of clonal hematopoiesis (CH) in neuroendocrine tumor (NET) patients prior to lutetium 177 Dotatate (Lu177): A prospective study
Sonbol Mohamad Bassam, Þorvarður R. Hálfdánarson(Mayo Clinic), Terra Lasho(Mayo Clinic), Jason S. Starr(Jacksonville College), Daniel H. Ahn(Mayo Clinic Hospital), Yael Kusne(University of Arizona), Rachel A. Eiring(Mayo Clinic), Tanios Bekaii‐Saab(WinnMed), Zaid Elsabbagh(Johns Hopkins University), Timothy J. Hobday(Mayo Clinic), Mrinal M. Patnaik(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic)
Cited by 0
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423